206 Results for "

P-ERK

" in MedChemExpress (MCE) Product Catalog:
Products (206)

206 Results for "P-ERK" in MCE Product Catalog:

  • Targets Recommended:
159
159 Publications Verification
Cat. No.: HY-10254
CAS No.: 391210-10-9
Purity:  99.95%
Synonyms: PD0325901; PD325901
Target:  

MEK Autophagy Apoptosis

Research Areas:  

Cancer

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Ki app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...
134
134 Cited Publications
Cat. No.: HY-18072
CAS No.: 1337531-36-8
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Cancer

GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM.
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-13820
CAS No.: 1337532-29-2
Purity:  99.66%
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Cancer

GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15816A
CAS No.: 1956366-10-1
Purity:  99.89%
Synonyms: BVD-523 hydrochloride; VRT752271 hydrochloride
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15816
CAS No.: 869886-67-9
Purity:  99.95%
Synonyms: BVD-523; VRT752271
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-12495
CAS No.: 1597403-47-8
Purity:  99.49%
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Neurological Disease

ISRIB (trans-isomer) is a potent inhibitor of PERK with an IC50 of 5 nM. ISRIB potently reverses the effects of eIF2α phosphorylation (IC50=5 nM).
loading...
    loading...
42
42 Cited Publications
Cat. No.: HY-119240
CAS No.: 324759-76-4
Purity:  99.05%
Target:  

PERK Autophagy

Research Areas:  

Neurological Disease Cancer

CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-100403
CAS No.: 298690-60-5
Purity:  99.67%
Target:  

mGluR

Research Areas:  

Cancer

Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM) .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-13032B
CAS No.: 1895049-20-3
Purity:  97.04%
Synonyms: GSK 525762C; I-BET 762 besylate
Research Areas:  

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-148439
CAS No.: 2765081-21-6
Purity:  99.68%
Synonyms: RMC-6236; RAS-IN-2
Target:  

Ras PERK

Research Areas:  

Cancer

Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-14268
CAS No.: 144060-53-7
Purity:  99.94%
Synonyms: TEI 6720; TMX 67
Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-12661A
CAS No.: 1883548-84-2
Purity:  99.67%
Target:  

PERK Autophagy

Research Areas:  

Cancer

AMG PERK 44 is an orally active and highly selective PERK inhibitor with an IC50 of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC50=7300 nM) and B-Raf (IC50 >1000 nM), respectively. AMG PERK 44 induces autophagy .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-14463
CAS No.: 912999-49-6
Purity:  99.92%
Synonyms: AT13387
Target:  

HSP

Research Areas:  

Cancer

Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC) .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-137207
CAS No.: 864388-65-8
Purity:  99.88%
Target:  

PERK

Research Areas:  

Neurological Disease

MK-28 is a potent and selective PERK activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N0777
CAS No.: 5041-82-7
Isorhamnetin-3-O-glucoside is an orally active natural compound. Isorhamnetin 3-O-glucoside increases P-ERK, ERK, P-Akt (Ser473), P-PI3K, and PDX-1. Isorhamnetin 3-O-glucoside downregulates C/EBPα and inhibits lipase. Isorhamnetin 3-O-glucoside reduces lipids and inhibits obesity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153343
CAS No.: 2732902-08-6
Purity:  99.92%
Synonyms: BAY 2965501
Target:  

DGK

Research Areas:  

Cancer

BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-130240
CAS No.: 2183470-09-7
Purity:  98.89%
Research Areas:  

Cancer

GCN2-IN-6 (Compound 6d) is a potent, and orally available GCN2 inhibitor confirmed by in-house enzymatic (IC50 of 1.8 nM) and cellular assays (IC50 of 9.3 nM). GCN2-IN-6 is also a eIF2α kinase PERK inhibitor with an IC50 of 0.26 nM (in enzymatic assay) and 230 nM (in cells) . GCN2-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0745
CAS No.: 94596-28-8
Senkyunolide I is an orally active, blood-brain barrier-permeable metabolite of Z-ligustilide (HY-N0401A) . Senkyunolide I is isolated from Ligusticum chuanxiong. Senkyunolide I upregulates p-Erk1/2 and Nrf2/HO-1, and inhibits Caspase 3. Senkyunolide I alleviates Apoptosis. Senkyunolide I increases the pain threshold in mice and reduces acetic acid-induced writhing responses in mice. Senkyunolide I improves neurological deficits, reduces infarct volume and alleviates cerebral edema in rats with focal cerebral ischemia-reperfusion injury. Senkyunolide I protects renal function and structural integrity in a mouse model of renal ischemia-reperfusion injury. Senkyunolide I is applicable to research related to focal cerebral ischemia-reperfusion injury, migraine, and renal ischemia-reperfusion injury .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N2450
CAS No.: 592-95-0
Sulforaphene, isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10 -4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signals .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0687
CAS No.: 2182-14-1
Vindoline is an orally active vinca alkaloid. Vindoline can be extracted from the leaves of Catharanthus roseus. Vindoline has a weak inhibitory effect on the self-assembly of tubulin. Vindoline alleviates Apoptosis, inhibits p-p65 and p-ERK. Vindoline improves diabetes, bone loss, osteoarthritis, and kidney damage .
loading...
    loading...